Table 1.
Autoantibodies detected in PSC patients
| Antibody | Prevalence (%) | (Median) | No. of patients | (Median) | No. of articles |
| Anti-BEC | 63 | (63) | 30 | (30) | 1[36] |
| pANCA | 26-94 | (68) | 13-86 | (30) | 19 (Table 2) |
| AMA | 0-9 | (0) | 15-73 | (37) | 10[44,61,78,89,102,112,137–140] |
| Anti-LKM | 0 | (0) | 10-80 | (37) | 7[44,89,112,137,140–142] |
| Anti-SLA/LP | 0 | (0) | 10-37 | (25) | 4[44,89,140,142] |
| ANA1 | 8-77 | (30) | 13-73 | (35) | 13[44,61,78,89,99,101,102,111,112,137–140] |
| SMA1 | 0-83 | (17) | 10-73 | (36) | 10[44,61,78,89,111,112,137–140] |
| ASCA | 44 | (44) | 25 | (25) | 1[115] |
| Anti-cardiolipin | 4-63 | (27) | 23-73 | (41) | 3[61,78,87] |
| Rheumatoid factor | 15 | (15) | 71 | (71) | 1[78] |
| AECA | 35 | (35) | 20 | (20) | 1[87] |
| Anti-TPO | 16 | (16) | 73 | (73) | 1[78] |
| Anti-GBM | 17 | (17) | 24 | (24) | 1[87] |
| Anti-sulfite oxidase | 33 | (33) | 39 | (39) | 1[130] |
| Anti-GSTT1 | 5 | (5) | 58 | (58) | 1[133] |
PSC: Primary sclerosing cholangitis; Anti-BEC: Antibodies against biliary epithelial cells (measured with flow cytometry); PANCA: Perinuclear antineutrophil cytoplasmic antibodies; ANA: Antinuclear antibodies; SMA: Smooth muscle antibodies; ASCA: Anti saccharomyces cerevisiae antibodies; AMA: Anti-mitochondrial antibodies; Anti-LKM: Liver-kidney microsomal antibodies; Anti-SLA/LP: Antibodies against soluble liver antigen/liver pancreas; AECA: Anti-endothelial cell antibodies; Anti-TPO: Antibodies against thyroid peroxidase; Anti-GBM: Antibodies against the glomerular basement membrane; Anti-GSTT1: Antibodies against glutathione S transferase theta 1.
In the largest cohort investigated, ANAs and/or SMAs were detected in 22% (24/111) of the PSC patients, but the frequency of each type was not given[143].